JP2022554186A5 - - Google Patents
Info
- Publication number
- JP2022554186A5 JP2022554186A5 JP2022524083A JP2022524083A JP2022554186A5 JP 2022554186 A5 JP2022554186 A5 JP 2022554186A5 JP 2022524083 A JP2022524083 A JP 2022524083A JP 2022524083 A JP2022524083 A JP 2022524083A JP 2022554186 A5 JP2022554186 A5 JP 2022554186A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- fibrin
- formula
- group
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962924997P | 2019-10-23 | 2019-10-23 | |
| US62/924,997 | 2019-10-23 | ||
| PCT/US2020/057198 WO2021081430A1 (en) | 2019-10-23 | 2020-10-23 | Fibrin-binding compounds for imaging and treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022554186A JP2022554186A (ja) | 2022-12-28 |
| JP2022554186A5 true JP2022554186A5 (https=) | 2023-10-26 |
Family
ID=75620290
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022524083A Pending JP2022554186A (ja) | 2019-10-23 | 2020-10-23 | 造影および処置のためのフィブリン結合化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240115744A1 (https=) |
| EP (1) | EP4048324A4 (https=) |
| JP (1) | JP2022554186A (https=) |
| KR (1) | KR20220104703A (https=) |
| CN (1) | CN114945388B (https=) |
| WO (1) | WO2021081430A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202313965D0 (en) * | 2023-09-13 | 2023-10-25 | Univ Oxford Innovation Ltd | Radiopharmaceutical |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI240632B (en) * | 2001-07-30 | 2005-10-01 | Epix Medical Inc | Purified peptides for peptide-based multimeric targeted contrast agents |
| WO2005001415A2 (en) * | 2003-05-23 | 2005-01-06 | Epix Pharmaceuticals, Inc. | Optically pure and enriched isomers of chelating ligands and contrast agents |
| WO2007047608A2 (en) * | 2005-10-14 | 2007-04-26 | Epix Pharmaceuticals, Inc. | Fibrin targeted therapeutics |
| CN101558081B (zh) * | 2006-12-11 | 2014-08-20 | 伯拉考成像股份公司 | 用于诊断和治疗应用的纤维蛋白结合肽缀合体 |
| PL2187965T3 (pl) * | 2007-08-17 | 2020-05-18 | Purdue Research Foundation | Koniugaty wiążący psma ligand-łącznik i sposoby ich zastosowania |
| WO2015038968A1 (en) * | 2013-09-13 | 2015-03-19 | The General Hospital Corporation | Activatable fibrin-binding probes |
| US20190216956A1 (en) * | 2016-07-27 | 2019-07-18 | The Trustees Of Columbia University In The City Of New York | Compositions for radiotherapy and uses thereof |
| US20190247520A1 (en) * | 2018-01-24 | 2019-08-15 | Carl A. Morris | Non-invasive detection of disease progression and therapeutic efficacy for muscular dystrophies and diseases |
-
2020
- 2020-10-23 EP EP20880168.8A patent/EP4048324A4/en active Pending
- 2020-10-23 KR KR1020227016766A patent/KR20220104703A/ko active Pending
- 2020-10-23 US US17/767,956 patent/US20240115744A1/en active Pending
- 2020-10-23 CN CN202080089490.0A patent/CN114945388B/zh active Active
- 2020-10-23 WO PCT/US2020/057198 patent/WO2021081430A1/en not_active Ceased
- 2020-10-23 JP JP2022524083A patent/JP2022554186A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101602992B1 (ko) | 아스코르브산을 사용한 방사성 약제 조성물의 안정화 | |
| AU2018274184B2 (en) | Novel PSMA-binding agents and uses thereof | |
| BR112021005931A2 (pt) | composto, complexo e composição farmacêutica | |
| JP7673056B2 (ja) | Ｇｒｐｒアンタゴニストを放射標識するための方法及びそれらのキット | |
| JPH0764802B2 (ja) | エステル置換ジアミンジチオール類およびそれらの放射線標識錯化合物 | |
| CN107438615B (zh) | 用于制备放射性核素络合物的方法和试剂盒 | |
| BR112020018155A2 (pt) | 177lu-dota-hynic-ipsma como um radiofármaco terapêutico dirigido ao antígeno prostático específico de membrana | |
| JPH04230224A (ja) | 放射性医薬製剤、その投与方法及びその製造方法 | |
| CN116217505B (zh) | 用于诊断或治疗表达前列腺特异性膜抗原癌症的新型标记靶向剂 | |
| JP2022554186A5 (https=) | ||
| US20240307560A1 (en) | Heptamethine carbocyanine dye-dota conjugates complexed with lutetium-177, yttrium-90, or gallium-68, and their uses for image-guided radiotherapy | |
| US9365599B2 (en) | N3S1 chelator-folate derivatives, preparation method thereof and composition for diagnosis or treatment of cancer containing the same as an active ingredient | |
| WO2018233798A1 (en) | Novel psma-binding agents and uses thereof | |
| US20120065367A1 (en) | Radioactively Labeled Substance | |
| RU2855011C1 (ru) | Способы мечения радиоактивными изотопами антагонистов grpr и наборы на для их осуществления | |
| Djokić et al. | Biological evaluation and comparison of three different procedures for labelling of amino acids tyrosine and lysine with technetium‐99m | |
| JP2025509631A (ja) | セラノスティック薬剤の標的送達 | |
| WO2025155818A1 (en) | Fibroblast activation protein-targeted radioligands with pharmacokinetic modulators | |
| WO2025153103A1 (zh) | 一种含氮化合物及其制备方法与用途 | |
| Adhikari et al. | Preliminary evaluation of an anthraquinone conjugated DOTA derivative as SPECT agent | |
| AU2010237040B9 (en) | Stabilization of radiopharmaceutical compositions using ascorbic acid | |
| KR20140057159A (ko) | Ｎ3ｓ1형의 새로운 킬레이터가 접합된 폴레이트 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암 진단 또는 치료용 조성물 | |
| KR20210048827A (ko) | 전립선 암의 영상 또는 치료를 위한 동위원소 표지 화합물 |